EGFR and lung adenocarcinoma: All KRAS and EGFR mutations were observed in patients with lung adenocarcinoma (5/26 patients each, representing 31.25%) in accordance with previously published data showing KRAS mutations in 18–32% of ADKs and only 1.6–7.1% of SSCs [36] and EGFR mutations in about one-third of ADKs [37,38] and in 3–18% of SSCs [39].